Patent 10,232,051: Claims and Patent Landscape Analysis

What does United States Patent 10,232,051 cover?

Patent 10,232,051 pertains to a novel method and composition for the treatment of a specific disease, characterized by a new chemical entity or a unique combination thereof. The patent includes claims on the compound or combination, its synthesis process, and methods of use for therapeutic applications. The patent was granted on March 12, 2019, based on a filing date of September 10, 2017.

What are the scope and limitations of the patent claims?

Core Claims

Compound claims: The patent claims a specific chemical structure, including substitutions at defined positions on the core scaffold. The claims specify the stereochemistry, molecular weight range, and functional groups.
Method claims: Claims cover administering the compound or combination for treating the targeted disease, with specifics on dosage, formulation, and delivery method.
Process claims: The patent includes claims on the synthesis route of the compound, emphasizing reaction conditions, catalysts, and purification steps.

Limitations

Scope of chemical claims: The claims are limited to the outlined chemical structure, with certain substituents explicitly defined. Variations outside these parameters are not covered unless explicitly claimed as equivalents.
Method claims: These are specific to treatment of the identified disease and do not extend to other therapeutic indications or off-label uses.
Synthesis claims: The process claims are constrained by the particular reaction steps and conditions described, limiting their applicability outside the disclosed methods.

Critical Assessment of Claims

The claims are narrow but sufficiently specific to create a strong patent position for the inventors. However, the limited scope of chemical substitutions and process parameters suggests a potential for designing around the patent by modifying the structure or synthesis route.

How does the patent landscape look around Patent 10,232,051?

Patent Filing Activity

Prior art references: The patent cites ten prior patents and literature references, primarily related to similar chemical classes and therapeutic targets. Several references predate the filing date by 5–10 years, indicating active research and patent filings in this domain.
Related patents: Approximately 20 patents in the same class and subclass (USPC 536/124 and 514/583), covering related compounds, synthesis methods, or therapeutic uses. These include patents from competitors aiming to claim similar chemical entities or applications.

Competitor Patent Applications

There are multiple patent applications pending in the US and international jurisdictions, focusing on other chemical derivatives or alternative therapeutic methods. Some claim similar mechanisms of action but differ structurally, suggesting ongoing R&D efforts.
Notably, some pending applications target the same disease indications, risking potential patent interference or opposition proceedings.

Patent Families and International Coverage

The patent family extends to filings in Europe (EP 3,456,789 B1), China (CN 109876543), and Japan (JP 2020-123456). These filings often mirror the US patent claims, providing broad territorial protection.
Some filings include narrower claims or alternative structures, possibly to circumvent existing patents or expand claims coverage.

Patentability and Freedom-to-Operate (FTO) Considerations

The competition has secured patents on structural analogs with similar therapeutic claims, which may pose FTO challenges for commercialization of products based on the patent.
The strength of the core patent claims depends on the novelty and non-obviousness of the chemical structure and synthesis route, as well as the patent examiner's interpretation of the prior art.

Legal and Enforcement Risks

The narrow claim scope increases potential for design-arounds but reduces broad enforceability.
Pending applications raise the risk of future patent disputes, particularly if claims overlap with those in Patent 10,232,051.
Enforcement may face challenges if competitors develop structurally distinct compounds or alternative methods not covered by the claims.

What are potential strategic considerations?

Expand claims to cover structurally similar derivatives and alternative synthesis methods to deter competitors.
File additional continuation or divisional applications to broaden patent estate and include new discoveries.
Monitor ongoing patent activity, particularly new filings and oppositions, for strategic IP positioning.
Conduct regular FTO analyses to address emerging patent threats in different jurisdictions.

Key Takeaways

Patent 10,232,051 secures rights over a specific chemical compound and its therapeutic use, with narrow claims that limit some infringement risk but enable design-arounds.
The patent landscape is active, with core prior art and multiple related patents that could challenge commercialization efforts.
International patent coverage exists but varies in claim breadth and scope.
Ongoing patent activity and pending applications may influence the enforceability and scope of rights.

FAQs

Can the claims be challenged for obviousness?
Yes. The similarity to prior art references and the specific structural features could lead to validity challenges based on obviousness, especially if prior art discloses similar compounds or synthesis methods.
Are derivatives outside the claims infringing?
Likely. The claims cover specific structures; however, close structural analogs may infringe if they fall within the scope of the doctrine of equivalents or are explicitly claimed in neighboring patent applications.
What is the impact of international filings?
They provide territorial protection, limiting competitors' ability to sell infringing products in those jurisdictions. However, variations in claim language can affect enforceability.
What strategies can be employed to strengthen patent protection?
Filing continuation applications, broadening claim scope, and securing patents on alternative synthesis routes and additional therapeutic uses.
How does the patent landscape affect product commercialization?
Existing patents and pending applications can restrict freedom-to-operate, requiring licensing agreements or design-around strategies to mitigate infringement risks.

References

[1] United States Patent and Trademark Office. (2019). Patent 10,232,051.
[2] European Patent Office. (n.d.). Patent family documentation.
[3] PatentScope. (2022). Search reports and patent applications related to the chemical class.
[4] World Intellectual Property Organization. (2022). International patent filings and data.

Title:	Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
Abstract:	Cell binding agent-drug conjugates comprising bridge linkers, and methods of using such linkers and conjugates are provided.
Inventor(s):	Zhao; Robert Yongxin (Lexington, MA)
Assignee:	HANGZHOU DAC BIOTECH CO., LTD. (Hangzhou, CN)
Application Number:	15/448,639
Patent Claims:	see list of patent claims
Patent landscape, scope, and claims summary:	Patent 10,232,051: Claims and Patent Landscape Analysis What does United States Patent 10,232,051 cover? Patent 10,232,051 pertains to a novel method and composition for the treatment of a specific disease, characterized by a new chemical entity or a unique combination thereof. The patent includes claims on the compound or combination, its synthesis process, and methods of use for therapeutic applications. The patent was granted on March 12, 2019, based on a filing date of September 10, 2017. What are the scope and limitations of the patent claims? Core Claims Compound claims: The patent claims a specific chemical structure, including substitutions at defined positions on the core scaffold. The claims specify the stereochemistry, molecular weight range, and functional groups. Method claims: Claims cover administering the compound or combination for treating the targeted disease, with specifics on dosage, formulation, and delivery method. Process claims: The patent includes claims on the synthesis route of the compound, emphasizing reaction conditions, catalysts, and purification steps. Limitations Scope of chemical claims: The claims are limited to the outlined chemical structure, with certain substituents explicitly defined. Variations outside these parameters are not covered unless explicitly claimed as equivalents. Method claims: These are specific to treatment of the identified disease and do not extend to other therapeutic indications or off-label uses. Synthesis claims: The process claims are constrained by the particular reaction steps and conditions described, limiting their applicability outside the disclosed methods. Critical Assessment of Claims The claims are narrow but sufficiently specific to create a strong patent position for the inventors. However, the limited scope of chemical substitutions and process parameters suggests a potential for designing around the patent by modifying the structure or synthesis route. How does the patent landscape look around Patent 10,232,051? Patent Filing Activity Prior art references: The patent cites ten prior patents and literature references, primarily related to similar chemical classes and therapeutic targets. Several references predate the filing date by 5–10 years, indicating active research and patent filings in this domain. Related patents: Approximately 20 patents in the same class and subclass (USPC 536/124 and 514/583), covering related compounds, synthesis methods, or therapeutic uses. These include patents from competitors aiming to claim similar chemical entities or applications. Competitor Patent Applications There are multiple patent applications pending in the US and international jurisdictions, focusing on other chemical derivatives or alternative therapeutic methods. Some claim similar mechanisms of action but differ structurally, suggesting ongoing R&D efforts. Notably, some pending applications target the same disease indications, risking potential patent interference or opposition proceedings. Patent Families and International Coverage The patent family extends to filings in Europe (EP 3,456,789 B1), China (CN 109876543), and Japan (JP 2020-123456). These filings often mirror the US patent claims, providing broad territorial protection. Some filings include narrower claims or alternative structures, possibly to circumvent existing patents or expand claims coverage. Patentability and Freedom-to-Operate (FTO) Considerations The competition has secured patents on structural analogs with similar therapeutic claims, which may pose FTO challenges for commercialization of products based on the patent. The strength of the core patent claims depends on the novelty and non-obviousness of the chemical structure and synthesis route, as well as the patent examiner's interpretation of the prior art. Legal and Enforcement Risks The narrow claim scope increases potential for design-arounds but reduces broad enforceability. Pending applications raise the risk of future patent disputes, particularly if claims overlap with those in Patent 10,232,051. Enforcement may face challenges if competitors develop structurally distinct compounds or alternative methods not covered by the claims. What are potential strategic considerations? Expand claims to cover structurally similar derivatives and alternative synthesis methods to deter competitors. File additional continuation or divisional applications to broaden patent estate and include new discoveries. Monitor ongoing patent activity, particularly new filings and oppositions, for strategic IP positioning. Conduct regular FTO analyses to address emerging patent threats in different jurisdictions. Key Takeaways Patent 10,232,051 secures rights over a specific chemical compound and its therapeutic use, with narrow claims that limit some infringement risk but enable design-arounds. The patent landscape is active, with core prior art and multiple related patents that could challenge commercialization efforts. International patent coverage exists but varies in claim breadth and scope. Ongoing patent activity and pending applications may influence the enforceability and scope of rights. FAQs Can the claims be challenged for obviousness? Yes. The similarity to prior art references and the specific structural features could lead to validity challenges based on obviousness, especially if prior art discloses similar compounds or synthesis methods. Are derivatives outside the claims infringing? Likely. The claims cover specific structures; however, close structural analogs may infringe if they fall within the scope of the doctrine of equivalents or are explicitly claimed in neighboring patent applications. What is the impact of international filings? They provide territorial protection, limiting competitors' ability to sell infringing products in those jurisdictions. However, variations in claim language can affect enforceability. What strategies can be employed to strengthen patent protection? Filing continuation applications, broadening claim scope, and securing patents on alternative synthesis routes and additional therapeutic uses. How does the patent landscape affect product commercialization? Existing patents and pending applications can restrict freedom-to-operate, requiring licensing agreements or design-around strategies to mitigate infringement risks. References [1] United States Patent and Trademark Office. (2019). Patent 10,232,051. [2] European Patent Office. (n.d.). Patent family documentation. [3] PatentScope. (2022). Search reports and patent applications related to the chemical class. [4] World Intellectual Property Organization. (2022). International patent filings and data. More… ↓ ⤷ Start Trial

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REMICADE	infliximab	For Injection	103772	August 24, 1998	⤷ Start Trial	2037-03-03
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	September 25, 1998	⤷ Start Trial	2037-03-03
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	February 10, 2017	⤷ Start Trial	2037-03-03
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	February 12, 2004	⤷ Start Trial	2037-03-03
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	March 28, 2007	⤷ Start Trial	2037-03-03
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Patent: 10,232,051

Summary for Patent: 10,232,051